|
Gene: SPAG16 |
Gene summary for SPAG16 |
Gene summary. |
Gene information | Species | Human | Gene symbol | SPAG16 | Gene ID | 79582 |
Gene name | sperm associated antigen 16 | |
Gene Alias | PF20 | |
Cytomap | 2q34 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q4G1A2 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
79582 | SPAG16 | LZE2T | Human | Esophagus | ESCC | 4.27e-02 | 3.86e-01 | 0.082 |
79582 | SPAG16 | LZE4T | Human | Esophagus | ESCC | 2.71e-08 | 2.16e-01 | 0.0811 |
79582 | SPAG16 | LZE8T | Human | Esophagus | ESCC | 6.02e-05 | 1.88e-01 | 0.067 |
79582 | SPAG16 | LZE20T | Human | Esophagus | ESCC | 3.56e-02 | 5.79e-02 | 0.0662 |
79582 | SPAG16 | LZE24T | Human | Esophagus | ESCC | 1.67e-19 | 7.61e-01 | 0.0596 |
79582 | SPAG16 | LZE6T | Human | Esophagus | ESCC | 1.43e-03 | 1.53e-01 | 0.0845 |
79582 | SPAG16 | P1T-E | Human | Esophagus | ESCC | 9.66e-07 | 1.85e-01 | 0.0875 |
79582 | SPAG16 | P2T-E | Human | Esophagus | ESCC | 1.06e-38 | 6.66e-01 | 0.1177 |
79582 | SPAG16 | P4T-E | Human | Esophagus | ESCC | 1.57e-13 | 2.47e-01 | 0.1323 |
79582 | SPAG16 | P5T-E | Human | Esophagus | ESCC | 3.58e-08 | 1.51e-01 | 0.1327 |
79582 | SPAG16 | P8T-E | Human | Esophagus | ESCC | 1.34e-44 | 6.95e-01 | 0.0889 |
79582 | SPAG16 | P9T-E | Human | Esophagus | ESCC | 1.82e-05 | 1.38e-02 | 0.1131 |
79582 | SPAG16 | P10T-E | Human | Esophagus | ESCC | 3.96e-23 | 3.19e-01 | 0.116 |
79582 | SPAG16 | P11T-E | Human | Esophagus | ESCC | 2.59e-09 | 4.68e-01 | 0.1426 |
79582 | SPAG16 | P12T-E | Human | Esophagus | ESCC | 2.34e-38 | 6.60e-01 | 0.1122 |
79582 | SPAG16 | P15T-E | Human | Esophagus | ESCC | 1.39e-21 | 4.54e-01 | 0.1149 |
79582 | SPAG16 | P16T-E | Human | Esophagus | ESCC | 3.93e-34 | 5.47e-01 | 0.1153 |
79582 | SPAG16 | P17T-E | Human | Esophagus | ESCC | 7.12e-06 | 3.14e-01 | 0.1278 |
79582 | SPAG16 | P20T-E | Human | Esophagus | ESCC | 2.64e-05 | 5.18e-03 | 0.1124 |
79582 | SPAG16 | P21T-E | Human | Esophagus | ESCC | 6.36e-03 | 2.52e-02 | 0.1617 |
Page: 1 2 3 4 5 6 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00991114 | Esophagus | ESCC | microtubule-based transport | 115/8552 | 190/18723 | 2.54e-05 | 2.15e-04 | 115 |
GO:00991113 | Oral cavity | OSCC | microtubule-based transport | 96/7305 | 190/18723 | 7.92e-04 | 4.27e-03 | 96 |
GO:00991115 | Thyroid | PTC | microtubule-based transport | 88/5968 | 190/18723 | 2.08e-05 | 2.08e-04 | 88 |
GO:009911112 | Thyroid | ATC | microtubule-based transport | 91/6293 | 190/18723 | 2.97e-05 | 2.48e-04 | 91 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SPAG16 | SNV | Missense_Mutation | rs79027980 | c.191N>G | p.Asp64Gly | p.D64G | Q8N0X2 | protein_coding | deleterious(0.04) | possibly_damaging(0.516) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SPAG16 | SNV | Missense_Mutation | c.322N>T | p.Val108Leu | p.V108L | Q8N0X2 | protein_coding | tolerated(0.08) | benign(0.079) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
SPAG16 | SNV | Missense_Mutation | c.427G>A | p.Glu143Lys | p.E143K | Q8N0X2 | protein_coding | tolerated(0.66) | benign(0.003) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
SPAG16 | SNV | Missense_Mutation | rs376825568 | c.1385T>C | p.Ile462Thr | p.I462T | Q8N0X2 | protein_coding | deleterious(0) | possibly_damaging(0.657) | TCGA-D1-A15X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SPAG16 | SNV | Missense_Mutation | c.422T>C | p.Val141Ala | p.V141A | Q8N0X2 | protein_coding | tolerated(0.74) | benign(0.011) | TCGA-D1-A17H-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
SPAG16 | SNV | Missense_Mutation | rs774991704 | c.1675G>A | p.Asp559Asn | p.D559N | Q8N0X2 | protein_coding | tolerated(0.14) | probably_damaging(0.996) | TCGA-D1-A17Q-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SPAG16 | SNV | Missense_Mutation | novel | c.313G>T | p.Val105Leu | p.V105L | Q8N0X2 | protein_coding | tolerated(0.18) | benign(0.022) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
SPAG16 | SNV | Missense_Mutation | rs371003630 | c.1873G>A | p.Gly625Ser | p.G625S | Q8N0X2 | protein_coding | tolerated(0.11) | probably_damaging(1) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SPAG16 | SNV | Missense_Mutation | rs144854983 | c.602N>A | p.Arg201Gln | p.R201Q | Q8N0X2 | protein_coding | deleterious(0.01) | benign(0.166) | TCGA-EO-A3AV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | CR |
SPAG16 | SNV | Missense_Mutation | novel | c.1175G>A | p.Gly392Asp | p.G392D | Q8N0X2 | protein_coding | deleterious(0) | probably_damaging(0.927) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |